Wall Street Bullish on Dividend Stocks Eli Lilly and ConocoPhillips for Potential 20%+ Gains
Analysts are projecting significant upside for two S&P 500 dividend payers despite modest yields. Eli Lilly (LLY) carries a 29% price target upside after its recent pullback, while ConocoPhillips (COP) shows 22% potential appreciation.
Lilly's stock decline followed disappointing Phase II results for oral weight-loss drug orforglipron, which showed 12.4% weight reduction versus 20.9% for injectable Zepbound. The market appears to be overlooking the company's broader pipeline and dominant position in metabolic therapeutics.
Energy giant ConocoPhillips represents a contrarian play as oil prices stabilize. Its disciplined capital allocation and shale assets position it to outperform peers during commodity price fluctuations.